Cancer Diagnostics – Products

In this article, Mark Lawler, professor of digital health, answers your questions about these revolutionary techniques and discusses the barriers to their implementation in the clinic. Prof. Lawler has an international reputation in cancer research and a focus on developing a molecular understanding of cancer to improve patient care, including through precision medicine.

High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance. Library preparation kit adds to Twist’s portfolio of tools to enable liquid biopsy applications

Tecan is announcing a streamlined solution portfolio to enable liquid biopsy applications, from upstream workflows to downstream analysis for genomics and proteomics applications.

The project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial. The Assay will be available as a service in the Babraham Institute’s Flow Cytometry Facility.

In an informative new blog post - AMSBIO reflects on a selection of the groundbreaking life science and biomedical research undertaken by its customers during 2023.

PlaqueTec announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

This application note presents the latest electrophoretic solutions for a more rapid assessment of cfDNA samples and optimal biomarker discovery.

Assays focus on accelerating cancer research.

CEO Gordon Sanghera discusses how Apple’s latest product announcement means complex processing required for DNA/RNA sequencing can now be run from the latest MacBook Pro™ or iMac ™.

To accelerate the discovery of new cancer biomarkers and new insights into the genetics of treatment-resistant tumors, it is crucial to gain a deeper understanding of the genomic and epigenomic variations in cancer.